For instance, Arun et al. administered subcutaneously injected mice with 16-mer gapmer targeting MALAT1 modified with alternative cEt-constrained nucleotides and phosphorothioate bonds before the spontaneous development of mammary tumors, resulting in a 50% reduction in metastatic burden, and a highly differentiated, cystic/ductular histological phenotype resembling MALAT1−/− genomic knockout mice (Arun et al., 2016). This evidence concerns the gene MALAT1 and breast cancer.